|
Amgen, Inc. (AMGN): Amgen: GSK’s Promacta Stealing Nplate’s Thunder
Seeking Alpha OB) Rituxan (Rituximab). If symptoms persist, surgical removal of the spleen, splenectomy, might be required. Amgen’s Nplate (romiplostim) and GlaxoSmithKline’s (GSK) Promacta (Eltrombopag) are two recently approved medications from a new class of … |
|
Gainers Buzz: Gilead Sciences, Inc. (NASDAQ:GILD), Cemex SAB de CV (ADR …
Market News Call It demonstrated “highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Should Investors Buy GILD After Yesterday’s Slump? Find … |
|
First IL-6–blocking drug nears approval for rare blood disorder
Nature.com However, there are few effective treatment options for people with HIV-negative MCD. Clinicians currently turn to steroids or chemotherapeutics, which can decrease symptoms of inflammation or B-cell growth but which cannot be used long term, or … |
OncLivePositive Idelalisib Data Halts Late-Stage CLL TrialOncLiveA phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab (Rituxan) has been stopped early following a positive interim analysis, according to a statement fro…
Idelalisib works against leukemia, trial stopped earlyCuretoday.com (press release)The phase 3 trial compared treatment with idelalisib and another drug, Rituxan (rituximab), to treatment with Rituxan alone in patients with CLL who were not eligible fo…
|
Gilead Stops Pivotal Trial Early as New Leukemia Drug Demonstrates Strong …
Equities.com The monitoring committee made its recommendation based upon a predefined protocol showing “highly statistically significant efficacy” for the primary endpoint of progression-free survival in patients receiving a cocktail of idelalisib and rituximab … |
|
FDA To Hold Public Teleconference on October 16 on Myalgic …
Sacramento Bee Rituximab is also showing promise in trials of ME/CFS patients. “The researchers and clinical experts involved in these studies are some of the top ME/CFS experts in the world and have the experience to know what outcome measures are best for ME/CFS … |
|
Gileads Idelalisib Encourages
Zacks.com Interim analysis of the randomized, double-blind, placebo-controlled study revealed that patients treated with idelalisib plus Roche’s (RHHBY) Rituxan (rituximab) exhibited statistically significant improvement in progression free survival compared to … |
|
From 2012 to 2022, the Rheumatoid Arthritis Market Will Grow Moderately …
The Providence Journal Pfizer/Takeda’s Jak inhibitor Xeljanz will likely be used after the TNF-alpha inhibitors initially, competing with Bristol-Myers Squibb/Ono Pharmaceutical’s Orencia, rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo’s Rituxan, Roche’s MabThera) and … |
StreetInsider.com (subscription)Pre-Open Stock Movers 10/10: (ACUR) (CHTP) (NFLX) Higher; (CTXS) (RT …StreetInsider.com (subscription)This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy …